https://www.selleckchem.com/pr....oducts/lenalidomide-
0% v 10.9%, OR=12.43, P.001). Participants were more likely to experience poor taste of food at any point in the study if they were being treated with denosumab (35.0% v 10.9%, OR=4.40, P=.02 or docetaxel (41.7% v 12.7%, OR=4.91, P=.022). Participants were more likely to experience ≥10% weight loss if experiencing poor taste of food (38.4% v 8.6%, OR=6.63, P=.01 or poor appetite (60.0% v 6.6%, OR=21.38, P.001). Clinicians should query patients for changes in taste and smell of food, especially if they are experien
Like
Comment
Share
